CITIUS ONCOLOGY, INC.
Datakwaliteit: 83%
CTOR
Nasdaq
Manufacturing
Chemicals
€ 0,66
▲
€ 0,02
(2,79%)
Marktkapitalisatie: 58,27 M
Prijs
€ 0,66
Marktkapitalisatie
58,27 M
Dagbereik
€ 0,62 — € 0,67
52-Weeksbereik
€ 0,49 — € 6,19
Volume
80.221
Openen € 0,63
50D / 200D Gem.
€ 0,96
30,94% below
50D / 200D Gem.
€ 1,59
58,51% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -12,85 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-52,06%
Boven sectorgemiddelde (-53,41%)
ROIC-43,72%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,83
Interest Coverage-109,05
Waardering
PE (TTM)
-2,47
Onder sectorgemiddelde (-1,48)
P/B Ratio1,00
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -2,5 | -1,5 |
| P/B | 1,0 | 1,6 |
| ROE % | -52,1 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -23,64 M |
| ROE | -52,06% | ROA | -23,44% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -12,85 M |
| ROIC | -43,72% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,83 |
| Interest Coverage | -109,05 | Asset Turnover | N/A |
| Working Capital | -7,56 M | Tangible Book Value | 58,41 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2,47 | Forward P/E | N/A |
| P/B Ratio | 1,00 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -22,05% | ||
| Market Cap | 58,27 M | Enterprise Value | 50,98 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,31 | Revenue / Share | N/A |
| FCF / Share | -0,15 | OCF / Share | -0,15 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 54,35% |
| SBC-Adj. FCF | -22,83 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net Income | -24,76 M | -21,15 M | 2,42 M | 380.811,0 |
| EPS (Diluted) | -0,34 | -0,31 | 0,27 | 0,12 |
| Gross Profit | — | — | — | — |
| Operating Income | -23,52 M | — | -1,01 M | -138.115,0 |
| EBITDA | — | — | — | — |
| R&D Expenses | 6,42 M | 4,93 M | — | — |
| SG&A Expenses | — | — | — | — |
| D&A | — | — | — | — |
| Interest Expense | 218.032,0 | — | — | — |
| Income Tax | 1,06 M | 576.000,0 | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total Assets | 100,94 M | 84,37 M | 72,62 M | 68,19 M |
| Total Liabilities | 56,08 M | 38,23 M | — | — |
| Shareholders' Equity | 44,87 M | 46,14 M | -1,99 M | 345.508,0 |
| Total Debt | — | — | — | — |
| Cash & Equivalents | — | — | — | — |
| Current Assets | 27,54 M | 10,97 M | 58.200,0 | 377.344,0 |
| Current Liabilities | 49,49 M | 32,70 M | 2,05 M | 31.836,0 |
{"event":"ticker_viewed","properties":{"ticker":"CTOR","listing_kind":"stock","pathname":"/stocks/ctor","exchange":"Nasdaq","country":"US"}}